^
    over1year
    Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors (clinicaltrials.gov)
    P1/2, N=107, Recruiting, Guangzhou Gloria Biosciences Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases • Immuno-oncology
    |
    Yutuo (zimberelimab) • GLS-012